Getting a grip on arthritis pain can be costly.
Although the scientific community has ushered in a great new era in the control of rheumatoid arthritis (RA) pain with the discovery of new drugs, the advances are futile if those who need these drugs cannot gain access to them because of the incredible cost. Pharmaceutical treatments for RA include nonsteroidal anti-inflammatory drugs and biologic therapy. A means must be found to improve drug coverage options for all of those suffering from this disease. As nurses, we have an important role to play as advocates for those suffering from RA. We can speak for those who have reduced access to these medications because of the increasing costs. We are able to explain to those in government, the pharmaceutical industry, private insurers, employers, the corporate world, Congress, our state and local communities, and our family and friends the many issues involved. We can advocate for further research on cost-effectiveness, and we can lobby those in Congress and state governments for improved benefits.
Shovein
J
J
School of Nursing California State University-Chico, USA. jshovein@csuchico.edu
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D003226:Congresses as Topic; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000191:economics*; D006801:Humans; D019458:Insurance Coverage / Q000191:economics / Q000592:standards; D006278:Medicare / Q000191:economics / Q000592:standards; D010146:Pain / Q000188:drug therapy / Q000191:economics*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal